Contact CFFC

May

Clinical Trial Alerts – May 2021

Cystic Fibrosis Foundation issued the following clinical trial alerts in May.

May 3, 2021

MAYFLOWERS: Study of pregnancy in women with cystic fibrosis

Status: Enrolling

Description: This observational study will evaluate the effects of CFTR modulators on women with CF during and after pregnancy. CFTR modulators are intended to help CFTR protein function closer to normal.

Age: 16 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: No FEV1 Limit

Number of Visits: 9

Length of Participation: 35 months

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04828382

Study to evaluate ARO-ENaC in adults with cystic fibrosis

Status: Enrolling

Description: This study will evaluate the safety and tolerability of ARO-ENaC, a drug intended to thin airway surface liquid. Multiple doses of the drug will be tested in adults with cystic fibrosis to find the optimal dose.

Age: 18 Years to 55 Years

Mutation: No Mutation Requirement

Fev1% Predicted: 40 to 99%

Number of Visits: 12

Length of Participation: 113 days

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04375514


Comments are closed.